Geode Capital Management LLC Grows Stock Holdings in Elanco Animal Health Incorporated $ELAN

Geode Capital Management LLC grew its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 7.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 9,425,533 shares of the company’s stock after acquiring an additional 640,098 shares during the period. Geode Capital Management LLC’s holdings in Elanco Animal Health were worth $213,343,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in ELAN. Huntington National Bank raised its holdings in Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after acquiring an additional 1,087 shares during the last quarter. Torren Management LLC purchased a new position in Elanco Animal Health in the 4th quarter worth approximately $46,000. Fifth Third Bancorp raised its holdings in Elanco Animal Health by 3,018.3% in the 3rd quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock worth $58,000 after acquiring an additional 2,807 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in Elanco Animal Health by 43.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,089 shares of the company’s stock worth $70,000 after acquiring an additional 938 shares during the last quarter. Finally, Nkcfo LLC purchased a new position in Elanco Animal Health in the 3rd quarter worth approximately $75,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ELAN has been the subject of a number of recent analyst reports. KeyCorp boosted their price objective on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. boosted their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. UBS Group restated a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Leerink Partners boosted their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Tuesday, February 24th. Finally, Citigroup boosted their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.20.

Elanco Animal Health Price Performance

Shares of ELAN opened at $23.65 on Wednesday. The firm has a market cap of $11.81 billion, a PE ratio of -47.30, a P/E/G ratio of 2.55 and a beta of 1.69. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. The firm has a fifty day simple moving average of $22.93 and a two-hundred day simple moving average of $23.33. Elanco Animal Health Incorporated has a 1-year low of $13.14 and a 1-year high of $27.72.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Jeffrey N. Simmons bought 4,971 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the purchase, the chief executive officer owned 171,971 shares in the company, valued at approximately $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rajeev A. Modi bought 4,911 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were bought at an average price of $20.35 per share, with a total value of $99,938.85. Following the completion of the purchase, the insider owned 160,812 shares in the company, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their position. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by insiders.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.